Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444743 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of MM-093 to Treat Patients With Uveitis
A Phase 2 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00444743 is a Phase 2 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT00444743, a Phase 2 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the tolerability, pharmacokinetics, pharmacodynamics, and biologic activity of MM-093 in patients with moderate to severe uveitis.
Interventions
- OTHER Placebo
- DRUG MM-093
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00444743
The ClinicalTrials.gov registry entry for NCT00444743 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00444743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00444743 about?
NCT00444743 is a clinical study titled "Phase 2 Study of MM-093 to Treat Patients With Uveitis". The purpose of this study is to evaluate the tolerability, pharmacokinetics, pharmacodynamics, and biologic activity of MM-093 in patients with moderate to severe uveitis.
What is the current status of trial NCT00444743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-02.
What interventions are being tested in trial NCT00444743?
The interventions under investigation include: Placebo (OTHER), MM-093 (DRUG).
Who is sponsoring clinical trial NCT00444743?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.